Renal Dysfunction in Heart Failure with Preserved Ejection Fraction: Insights from the RELAX Trial

Patients with heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD) represent a high-risk phenotype. The Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) trial enrolled a high proportion of CKD participants, allowing investigation into differences in HFpEF by CKD status.

Source: Journal of Cardiac Failure - January 9, 2020 Category: Cardiology Authors: Ravi B. Patel, Rupal Mehta, Margaret M. Redfield, Barry A. Borlaug, Adrian F. Hernandez, Sanjiv J. Shah, Ruth F. Dubin Tags: Original Investigation Source Type: research